NCT05024032: A reported trial by Eli Lilly and Company
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05024032 |
|---|---|
| Title | Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 1, 2021 |
| Completion date | Dec. 27, 2022 |
| Required reporting date | Dec. 27, 2023, midnight |
| Actual reporting date | Dec. 26, 2023 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |